Prediction Case File
YouTubeEvaluation Complete

Friends! In this video, I'm going to do a Netflix stock analysis & discuss the risks and upside potential of NFLX stock

1 extracted signal · 1 resolved · 0 still active

The Patient Investor profile imageThe Patient InvestorIndependent analyst profile
Source published
13 Jan 2026, 00:28 UTC
Recorded by Tahlil Plus
18 May 2026, 20:23 UTC
Video preview for Friends! In this video, I'm going to do a Netflix stock analysis & discuss the risks and upside potential of NFLX stock
Source overview

AI-generated source summary

The analysis focuses on Netflix (NFLX) with a 6-month timeframe. The stock is currently trading at $89.00 and has experienced significant drawdowns over the past six months, down 28.17%. The presenter notes historical drawdowns of up to 80% and more recently 74% from its peak. Fundamental analysis highlights the company's revenue growth of 17% year-over-year and a net profit margin of 22%. The price-to-earnings (P/E) ratio is currently 37, with projections to reach 30 by 2029 and 25 by 2030. The presenter calculates that to double their money, investors would need to buy at $87, implying an upside of 96% with a 14.4% CAGR. However, a more conservative target of $73 with a 25x P/E multiple suggests a 63% upside with a 10.3% CAGR. The presenter concludes that at current levels, Netflix is fairly valued, not overvalued or a bargain, suggesting a potential buying opportunity if the price drops below $80.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
1
Extracted from this source
Open
0
Still being tracked
Successful
0
Resolved successfully
Failed
1
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
0%
1 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    1 eligible signal linked to this case.

  4. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  5. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  6. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

Analyst snapshot

The Patient Investor

Platform-wide history, separate from this source evaluation.

Reliability
47.9
Tracked signals
355
Historical success
34.9%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail